Paclitaxel

Indication: Malignant neoplasms of breast

Medicine type: Chemical agent

List type: Complementary

Formulations: Parenteral > General injections > IV: 6 mg per mL

EML status history:
- First added in 2011 (TRS 965)
- Changed in 2015 (TRS 994)

Sex: All

Age: Adolescents and adults

Therapeutic alternatives: The recommendation is for this specific medicine

Patent information: Patents have expired in most jurisdictions

Read more about patents.

Wikipedia: Paclitaxel

DrugBank: Paclitaxel

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for early-stage breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for early-stage breast cancer is attached.

Expert Committee report